ERBB2 and breast cancer: The discrepancies in pHER2Y1248 expression might be explained by differences in assays sensitivity, scoring systems, cut-off values used for the evaluation of pHER2 expression, and likely difference in the degree of phosphorylation/activation of HER2 in biologically distinct BC patient cohorts.